Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor

Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by poor prognosis, early recurrence, and the lack of durable chemotherapy responses and specific targeted treatments. In this preclinical study, we examines Tiliroside (TS, C(30)H(26)O(13)), as one of the ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Rui, Yang, Hongxing, Ling, Changquan, Lu, Lingeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685933/
https://www.ncbi.nlm.nih.gov/pubmed/36424626
http://dx.doi.org/10.1186/s12935-022-02786-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685933/
https://www.ncbi.nlm.nih.gov/pubmed/36424626
http://dx.doi.org/10.1186/s12935-022-02786-6

Ejemplares similares